Conception of National Biologics Registry for Pediatric Rheumatology: Need of the Hour and the Way Forward

Narendra Kumar Bagri; Sathish Kumar; Athimalaipet V Ramanan

doi:10.1007/s13312-022-2661-8

Conception of National Biologics Registry for Pediatric Rheumatology: Need of the Hour and the Way Forward

Narendra Kumar Bagri^*, Sathish Kumar, Athimalaipet V Ramanan

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

3 Citations (Scopus)

Abstract

The outcome for children with rheumatic diseases has been dramatically altered by the use of biological therapies. Increasing use of these agents will need careful monitoring for long term safety, particularly in children. Current data on safety of these drugs stem exclusively from Western literature. There is clear need for a registry of all children with rheumatic diseases who are commenced on biological agents to ensure appropriate pharmacovigilance. In this perspective, we discuss the need for and the role of a biologics registry for children with rheumatic diseases in India.

Original language	English
Pages (from-to)	913-915
Number of pages	3
Journal	Indian Pediatrics
Volume	59
Issue number	12
Early online date	9 Sept 2022
DOIs	https://doi.org/10.1007/s13312-022-2661-8
Publication status	Published - 15 Dec 2022

Keywords

Child
Humans
Biological Products/adverse effects
Rheumatology
Rheumatic Diseases/drug therapy
Registries
Biological Factors/therapeutic use

Access to Document

10.1007/s13312-022-2661-8

Handle.net

Persistent link

Cite this

@article{bd8189753cd1450ebb585023c4dbacec,

title = "Conception of National Biologics Registry for Pediatric Rheumatology: Need of the Hour and the Way Forward",

abstract = "The outcome for children with rheumatic diseases has been dramatically altered by the use of biological therapies. Increasing use of these agents will need careful monitoring for long term safety, particularly in children. Current data on safety of these drugs stem exclusively from Western literature. There is clear need for a registry of all children with rheumatic diseases who are commenced on biological agents to ensure appropriate pharmacovigilance. In this perspective, we discuss the need for and the role of a biologics registry for children with rheumatic diseases in India.",

keywords = "Child, Humans, Biological Products/adverse effects, Rheumatology, Rheumatic Diseases/drug therapy, Registries, Biological Factors/therapeutic use",

author = "Bagri, \{Narendra Kumar\} and Sathish Kumar and Ramanan, \{Athimalaipet V\}",

year = "2022",

month = dec,

day = "15",

doi = "10.1007/s13312-022-2661-8",

language = "English",

volume = "59",

pages = "913--915",

journal = "Indian Pediatrics",

issn = "0019-6061",

publisher = "Springer",

number = "12",

}

TY - JOUR

T1 - Conception of National Biologics Registry for Pediatric Rheumatology

T2 - Need of the Hour and the Way Forward

AU - Bagri, Narendra Kumar

AU - Kumar, Sathish

AU - Ramanan, Athimalaipet V

PY - 2022/12/15

Y1 - 2022/12/15

N2 - The outcome for children with rheumatic diseases has been dramatically altered by the use of biological therapies. Increasing use of these agents will need careful monitoring for long term safety, particularly in children. Current data on safety of these drugs stem exclusively from Western literature. There is clear need for a registry of all children with rheumatic diseases who are commenced on biological agents to ensure appropriate pharmacovigilance. In this perspective, we discuss the need for and the role of a biologics registry for children with rheumatic diseases in India.

AB - The outcome for children with rheumatic diseases has been dramatically altered by the use of biological therapies. Increasing use of these agents will need careful monitoring for long term safety, particularly in children. Current data on safety of these drugs stem exclusively from Western literature. There is clear need for a registry of all children with rheumatic diseases who are commenced on biological agents to ensure appropriate pharmacovigilance. In this perspective, we discuss the need for and the role of a biologics registry for children with rheumatic diseases in India.

KW - Child

KW - Humans

KW - Biological Products/adverse effects

KW - Rheumatology

KW - Rheumatic Diseases/drug therapy

KW - Registries

KW - Biological Factors/therapeutic use

U2 - 10.1007/s13312-022-2661-8

DO - 10.1007/s13312-022-2661-8

M3 - Article (Academic Journal)

C2 - 36089846

SN - 0019-6061

VL - 59

SP - 913

EP - 915

JO - Indian Pediatrics

JF - Indian Pediatrics

IS - 12

ER -

Conception of National Biologics Registry for Pediatric Rheumatology: Need of the Hour and the Way Forward

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this